Osemozotan

Drug Profile

Osemozotan

Alternative Names: MKC-242; MN-305

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mitsubishi Pharma Corporation
  • Developer Mitsubishi Tanabe Pharma Corporation
  • Class Antidepressants; Anxiolytics; Irritable bowel syndrome therapies; Small molecules
  • Mechanism of Action Serotonin 1A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Anxiety disorders; Generalised anxiety disorder; Insomnia; Irritable bowel syndrome; Major depressive disorder

Most Recent Events

  • 08 May 2014 Osemozotan is no longer licensed to MediciNova (http://www.mt-pharma.co.jp/e/develop/pipeline/e_pipeline1403.pdf)
  • 08 May 2014 Suspended - Phase-II for Anxiety disorders in Japan (PO)
  • 08 May 2014 Suspended - Phase-II for Insomnia in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top